Donanemab is a humanized monoclonal antibody targeting amyloid-beta plaques for early Alzheimer's disease research. It has demonstrated efficacy in reducing amyloid and tau pathology in clinical trials, supporting its investigation in both in vitro and in vivo models of neurodegenerative disease.